Related Experiment Videos
The integrin alpha 4 beta 1 (VLA-4) as a therapeutic target
1Cytel Corporation, San Diego, CA 92121, USA.
Ciba Foundation Symposium
|January 1, 1995
Summary
Small molecule inhibitors targeting leukocyte integrin alpha 4 beta 1 (VLA-4) show promise for treating chronic inflammatory diseases. These VLA-4 inhibitors offer a potential therapeutic strategy beyond antibody-based treatments.
Area of Science:
- Immunology
- Pharmacology
- Drug Discovery
Background:
- Leukocyte integrin alpha 4 beta 1 (VLA-4) plays a key role in chronic inflammatory disorders.
- Current in vivo studies utilize anti-alpha 4 antibodies to validate VLA-4 as a therapeutic target.
- Repeated administration of antibodies for chronic conditions presents challenges.
Purpose of the Study:
- To develop and evaluate low molecular weight inhibitors of alpha 4 beta 1 (VLA-4).
- To assess the therapeutic potential of VLA-4 inhibitors in animal models of chronic inflammation.
Main Methods:
- Development of small molecule alpha 4 beta 1 inhibitors.
- Testing of inhibitors in established animal models of chronic inflammation.
Main Results:
- Successfully developed low molecular weight alpha 4 beta 1 inhibitors.
- Demonstrated therapeutic promise of these inhibitors in animal models.
Conclusions:
- Low molecular weight alpha 4 beta 1 inhibitors represent a viable therapeutic approach for chronic inflammatory diseases.
- These small molecule antagonists offer a practical alternative to antibody-based therapies for long-term treatment.